Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience

Autor: Steven M. Devine, Christina Matthews, Marcin Puto, Junan Li, Yvonne A. Efebera, Filiz Yucebay, Julianna Roddy, Basem M. William, Samantha Jaglowski, Don M. Benson, Sam Penza, Sumithira Vasu, Leslie A. Andritsos
Rok vydání: 2019
Předmět:
Adult
Male
Cancer Research
medicine.medical_specialty
Drug Resistance
Graft vs Host Disease
Kaplan-Meier Estimate
Antibodies
Monoclonal
Humanized
Single Center
Gastroenterology
Young Adult
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
First line therapy
Tocilizumab
immune system diseases
hemic and lymphatic diseases
Internal medicine
Acute graft versus host disease
Humans
Transplantation
Homologous
Medicine
Glucocorticoids
Aged
Retrospective Studies
integumentary system
business.industry
Hematopoietic Stem Cell Transplantation
Hematology
Middle Aged
Allografts
Treatment Outcome
surgical procedures
operative
Oncology
chemistry
Hematologic Neoplasms
030220 oncology & carcinogenesis
Acute Disease
Disease Progression
Female
Stem cell
Steroid refractory
business
Complication
Immunosuppressive Agents
030215 immunology
Zdroj: Leukemia & Lymphoma. 60:2223-2229
ISSN: 1029-2403
1042-8194
Popis: Acute graft-versus-host-disease (aGVHD) is a complication after allogeneic stem cell transplant. After the failure of treatment with high dose corticosteroids, steroid-refractory aGVHD (SR aGVHD) is associated with high rates of mortality. Tocilizumab has evidence of activity in SR aGVHD. For patients ineligible for trials, the OSU James Comprehensive Cancer Center has been utilizing tocilizumab as first-line therapy for SR aGVHD. We retrospectively report on 15 patients who received tocilizumab. aGVHD grading and responses were based on consensus criteria. Median age at transplant was 49 years. Median time to tocilizumab administration was 9 days (range, 3-16). Six patients had complete responses (40%) with a resolution of aGVHD. From the last contact, median overall survival for responders was not yet reached vs. 31 days for non-responders (
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje